Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 46 to 56 of 56 results for durvalumab

  1. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [TSID12181]

    Awaiting development [GID-TA11747] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]

    In development [GID-TA11115] Expected publication date: 04 February 2026

    Technology appraisal guidance
    In development

  3. Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]

    Awaiting development [GID-TA11671] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]

    Awaiting development [GID-TA10967] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    2 September 2020
    View recommendations

    Sections for TA645

  6. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA692

  7. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-TA11569] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    In development [GID-TA11624] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

    Discontinued [GID-TA10783]

    Technology appraisal guidance
    Discontinued

  10. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Technology appraisal guidance
    Published
    1 May 2019

  11. More than 400 people could benefit from life-extending advanced lung cancer treatment

    Durvalumab recommended as an option for treating non-small-cell lung cancer.

    News
    Last updated
    18 January 2024